06:03 PM EDT, 10/03/2024 (MT Newswires) -- CervoMed ( CRVO ) filed a registration statement Thursday with the US Securities and Exchange Commission covering the potential sale of up to $250 million of its securities from time to time in one or more offerings.

The filing covers common and preferred stock, debt securities, warrants, and units.

CervoMed ( CRVO ) said it intends to use the net proceeds from the offering to support the research and development of its primary drug candidate, neflamapimod, and for general corporate purposes.